Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Should It Be Considered?

Cells. 2022 Nov 2;11(21):3463. doi: 10.3390/cells11213463.


Hematopoietic stem cell transplantation (HSCT) is widely used in benign and malignant hematological diseases. During the last decade, HSCT, mainly autologous, also gained increasing attention in the treatment of refractory autoimmune diseases. Crohn's disease (CD) is an inflammatory bowel disease leading to transmural inflammation potentially affecting all parts of the luminal gastrointestinal tract. Despite improving therapeutic options, including various biologics, some patients are refractory to all lines of available conservative therapy, leading to increased morbidity and reduced quality of life. Apart from surgery, HSCT might be a reasonable treatment alternative for refractory CD patients. This review aims to describe the current role of HSCT in CD and discusses the procedure, the correct patient selection, the clinical efficacy from initial remission to following relapse rates, and complications of this treatment.

Keywords: Crohn’s disease; chemotherapy; hematopoietic stem cell transplantation; inflammatory bowel disease.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Crohn Disease* / therapy
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Inflammatory Bowel Diseases* / etiology
  • Quality of Life
  • Transplantation, Autologous

Grants and funding

This research received no external funding.